Akili Announces Exclusive Licensing Agreement for New Digital Technology Integrating Neural Systems Targeting and Physical Activity as Novel Cognitive Dysfunction Treatment Platform
Summary
The technology is being studied in multiple clinical trials and holds potential to improve cognitive function in patients with a wide range of medical conditions.The ability to generate those benefits through technology that directly engages brain networks associated with cognitive control is extremely exciting,” said Adam Gazzaley, Founder & Executive Director of Neuroscape and Co-founder and Chief Scientific Advisor at Akili.The newly licensed technology represents the latest in a series of potential new digital medicines Akili is pursuing that directly target and activate specific neural networks in the brain to treat psychological and neurological disorders.Both through strategic licensing and internal discovery efforts, Akili actively seeks out new innovative technologies with the potential to target specific brain networks involved in cognitive function.Akili is advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including ADHD, MDD, ASD and various inflammatory diseases.